华森制药(002907) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥191,690,822.57, representing a 16.24% increase compared to ¥164,915,909.05 in the same period last year[9]. - Net profit attributable to shareholders for Q1 2019 was ¥31,231,261.11, up 6.05% from ¥29,449,190.31 in the previous year[9]. - The net profit after deducting non-recurring gains and losses was ¥30,738,966.13, reflecting a 16.59% increase from ¥26,364,609.16 year-on-year[9]. - Basic earnings per share for Q1 2019 were ¥0.0781, up 6.11% from ¥0.0736 in the same period last year[9]. - The company reported a net profit of CNY 36,290,691.39 for Q1 2019, compared to CNY 31,186,000.00 in Q1 2018, marking an increase of 16.5%[66]. - The net profit for the current period is CNY 31,346,020.12, compared to CNY 29,054,769.73 in the previous period, reflecting an increase of about 7.9%[76]. - The total profit for the current period is CNY 36,875,115.91, compared to CNY 34,182,082.04 in the previous period, reflecting an increase of approximately 7.9%[76]. Cash Flow - The net cash flow from operating activities was -¥40,644,513.06, a significant decline of 1,679.61% compared to ¥2,573,075.07 in the same period last year[9]. - The cash flow from operating activities for the current period is CNY 129,620,137.50, slightly down from CNY 133,374,301.08 in the previous period, indicating a decrease of about 2.8%[80]. - Operating cash inflow totaled CNY 131,999,307.70, a decrease from CNY 140,254,239.11 in the previous period, reflecting a decline of approximately 8.9%[83]. - Operating cash outflow amounted to CNY 172,643,820.76, compared to CNY 137,681,164.04 in the prior period, representing an increase of about 25.4%[83]. - Total cash inflow from operating activities was CNY 105,985,393.58, a decrease from CNY 119,899,836.19 in the prior period[89]. - Total cash outflow from operating activities was CNY 137,738,705.89, compared to CNY 105,621,614.66 in the previous period, indicating an increase of approximately 30.4%[89]. - The ending balance of cash and cash equivalents stood at CNY 34,886,126.47, down from CNY 62,084,727.95 in the previous period[86]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,130,167,664.91, an increase of 3.34% from ¥1,093,630,023.08 at the end of the previous year[9]. - The net assets attributable to shareholders increased by 3.77% to ¥860,145,311.08 from ¥828,914,049.97 at the end of the previous year[9]. - Total liabilities reached CNY 270,022,353.83, compared to CNY 264,715,973.11 previously[52]. - The company's total assets were CNY 1,130,167,664.91, an increase from CNY 1,093,630,023.08[55]. - The company's equity attributable to shareholders was CNY 860,145,311.08, up from CNY 828,914,049.97[55]. - Accounts payable rose by 34.98% to ¥81,370,905.01 from ¥60,285,618.34, mainly due to increased project and equipment payments[27]. Research and Development - R&D expenses increased by 334.69% to ¥6,378,607.70 from ¥1,467,385.10, reflecting the company's increased investment in research and development[27]. - Research and development expenses increased significantly to CNY 6,378,607.70, compared to CNY 1,467,385.10 in the previous year, marking a 334.5% rise[66]. - Research and development expenses have significantly increased to CNY 6,580,988.65 from CNY 1,669,766.05, indicating a rise of approximately 294.5%[73]. Government Subsidies and Other Income - The company received government subsidies amounting to ¥362,800.00 during the reporting period[9]. - The company received government subsidies and guarantees that were significantly lower, leading to a 65.42% decrease in cash received from other operating activities to ¥2,379,170.20 from ¥6,879,938.03[27]. - The company has reported an increase in other income to CNY 362,800.00 from CNY 250,000.00, which is an increase of approximately 45%[73]. Shareholder Information - The total number of shareholders at the end of the reporting period was 27,161[14]. - The company had no violations regarding external guarantees during the reporting period[40]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[41]. Accounting Policies - The company has implemented new accounting policies effective January 1, 2019, related to financial instruments, revenue, and leases[93].